Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug...

Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease May 28, 2026 Download PDF Share Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026 . The US Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) for venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of type 3 Gaucher disease (GD3)

saved by

• ochre

related reading

• A new brain‐penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher diseasepmc.ncbi.nlm.nih.gov
• Eliglustat - Wikipediaen.wikipedia.org
• New Genzyme pill will cost patients $310,250 a year - The Boston Globeweb.archive.org
• Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birthpmc.ncbi.nlm.nih.gov
• GBA Variants and Parkinson Disease: Mechanisms and Treatmentspmc.ncbi.nlm.nih.gov
• TP-060 (CAS 2601393-20-6)caymanchem.com
• Targeting UGCG overcomes resistance to lysosomal autophagy inhibitionpmc.ncbi.nlm.nih.gov
• UGCG and the glycosphingolipid rheostat: a metabolic checkpoint governing immune activation and tumor immune evasion | Signal Transduction and Targeted Therapynature.com
• U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1takeda.com
• Research Areas - Svendsen Lab | Cedars-Sinaicedars-sinai.edu
• FDA Approves First CRISPR Gene Editing Treatment for Sickle Cell Disease | Scientific Americanscientificamerican.com
• Sacubitril-Valsartan - StatPearls - NCBI Bookshelfncbi.nlm.nih.gov